B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients

This study was designed to determine how B cell depletion changes lymphocyte profiles. During a phase IIa clinical trial with ublituximab, a novel CD20 antibody, blood was collected from 48 MS patients at 11 time points over 24  weeks and the lymphocyte profiles were analyzed by flow cytometry.

Source: Journal of Neuroimmunology - May 2, 2019 Category: Allergy & Immunology Authors: Amy E. Lovett-Racke, Matthew Gormley, Yue Liu, Yuhong Yang, Calsey Graham, Sibyl Wray, Michael K. Racke, Richard Shubin, Cary Twyman, Enrique Alvarez, Ann Bass, James L. Eubanks, Edward Fox Source Type: research